Coronary artery ectasia (CAE) is a rare condition defined as the dilatation of coronary artery to at least 1.5 times larger than the normal adjacent coronary artery. Clinical manifestations of CAE vary, ranging from asymptomatic to ST-segment elevation myocardial infarction (STEMI). Because of its rarity and clinical diversity, the best treatment strategy and prognosis for CAE remain unclear. We describe a case of STEMI caused by intracoronary thrombus formation within an ectatic area in a patient with liver cirrhosis (LC). The patient was successfully managed by thrombus aspiration only, without balloon angioplasty or stent implantation, and maintained by dual antiplatelet therapy with aspirin and ticagrelor, a potent new P2Y12 inhibitor.
been diagnosed with LC caused by hepatitis B 5 years previously and was taking adefovir 10 mg qd and lamivudine 100 mg qd. He had never smoked and had no family history of CAD. On physical examination, his blood pressure was 90/50 mmHg, and his heart rate was 54 beats/min. The patient's height was 178 cm, and his body weight was 80 kg.
His mental status was alert. His heart and lung sounds were nonspecific. Chest radiography was unremarkable, with no evidence of pulmonary edema. Electrocardiogram showed ST-segment elevation on the II, III, and aVF leads with reciprocal changes on the I and aVL leads (Fig. 1) . Transthoracic echocardiogram revealed hypokinesia on the inferior (Fig. 2) . Intracoronary infusion of glycoprotein IIb/IIIa inhibitor (abciximab 0.25 mg/kg) and thrombus aspiration were performed. The aspirated material was considered red thrombi (Fig. 3) . After aspiration thrombectomy, diffuse huge ectasia-induced sluggish and turbulent blood flow and small attached thrombi without residual stenosis were observed at the previously occluded lesion, and flow grade 3 was obtained (Fig. 4) .
Therefore, we completed the coronary intervention without further angioplasty and decided to treat the patient conservatively under intensive monitoring, focusing on both ischemic and bleeding events in the coronary care unit (CCU). Dual antiplatelet therapy with aspirin 100 mg qd and ticagrelor 90 mg bid was maintained; atorvastatin 10 mg qd, bisoprolol 2.5 mg qd, and ramipril 2.5 mg qd were added. cases of whole CAE without a known cause. [7] CAE is most commonly associated with coronary atherosclerosis; however, 30% of cases are caused by other conditions, such as congenital connective tissue disorders (Marfan syndrome, Ehlers-Danlos syndrome), infection (syphilis), Kawasaki disease, and other forms of vasculitis.
[8] We could not find any other cause of CAE in our patient except for atherosclerosis. Based on etiology, CAE is divided into three types: congenital, acquired atherosclerotic, and isolated or inflammatory. Although the latter type is also acquired, it is not directly related to atherosclerosis. Several conditions, like inflammation, trauma, connective tissue disorders, infections, and the use of certain drugs, lead to this type of ectasia. [9] The atherosclerotic type has been reported to be associated with risk factors such as male sex, hypertension, diabetes mellitus, dyslipidemia, history of stroke, and cigarette smoking, which are similar to those of CAD in general. [1, 3, 9] CAE is often related to endothelial damage and microvascular dysfunction, and dilation of a coronary segment tends to result in stasis, delayed antegrade filling, and segmental back flow. Such conditions cause various manifestations, such as sluggish and turbulent blood flow, coronary vasospasm, spontaneous dissection, or thrombus formation, and these mechanisms can contribute to diverse clinical syndromes. [1, 3, 7, 10] Therefore, the clinical manifestations of CAE can range from asymptomatic or silent ischemia to STEMI as a result of sudden total occlusion by a thrombus.
Interestingly, the incidence of myocardial infarction and mortality in atherosclerotic CAE is similar to that of atherosclerotic CAD without ectasia. [1, 3] Meanwhile, a lower incidence of ACS has been reported in patients with chronic liver disease, including liver cirrhosis. [5] Several biochemical changes associated with chronic liver disease might explain the characteristics of less atherosclerotic plaque vulnerability, which is an important factor for developing acute coronary events. Coagulation abnormalities, thrombocytopenia, platelet dysfunction, reduced production of total cholesterol and LDL cholesterol, significantly increased activity of nitric oxide, increased plasma estrogen level, [11] and high activity of transforming growth factor beta, a potent inhibitor of the proliferation of cardiac smooth muscle cells, [12] are considered to contribute to the lower incidence of ACS. Those changes also lead to systemic vasodilatation that causes hyperdynamic circulation with greater coronary blood flow and a reduction in systemic vascular resistance in advanced cirrhosis. [5] Traditionally, LC as hypocoagulable status has been thought to be caused by nearly all procoagulant factors being produced less than the anticoagulant factors are produced. The degree of thromobocytopenia and prolongation of PT-INR has been taken as a marker of the severity of coagulopathy. [13] The development of STEMI in the present case was probably influenced by cardiovascular risk factors related to ectasia, [3, 14] Systemic anticoagulation therapy may be strongly indicated for severe coronary artery dilatation (greater than twice the size of the healthy reference diameter), which has been reported to have higher morbidity and mortality rates. [9] Although anticoagulation therapy is important for preventing the recurrence of myocardial infarction in the current case, we decided to use dual-antiplatelet therapy with aspirin and ticagrelor, a potent new P2Y 12 inhibitor, considering his mean INR of about 2.0. [15] Treatment varies depending on the type of CAE, except for antiplatelet and anticoagulation therapies. In our case, LC was another factor to consider when developing the treatment plan. Because patients with atherosclerotic CAE have similar risk factors and mortality rates to patients with atherosclerotic CAD without ectasia, the initial treatment for CAE should be considered to be similar to the treatment for atherosclerotic CAD, as per current guidelines. This includes aggressive control of risk factors such as hypertension, diabetes mellitus, dyslipidemia, and smoking. [3] Medical treatment, including statins, beta blockers, and reninangiotension system inhibitors, are helpful for treating CAE.
Statins have been shown to be safe in patients with liver disease, with complication rates similar to those in patients without liver disease. [16] With respect to beta blockers, cardio-selective beta blockers can be used for cardiac comorbidities, such as CAD and congestive heart failure, in early cirrhosis. [17] Limited data suggest that nitroglycerin, even when given sublingually, should be used with caution due to the risk of accelerating ischemia by sluggish coronary blood flow resulting from stasis in CAE patients without stenosis.
[14] Other types of congenital and isolated or inflammatory CAE require consultation with specialists for surgical treatment or immunosuppressive and anti-inflammatory drug therapy depending on the underlying etiology. [8] Surgical and percutaneous approaches for CAE have been reported. The ideal surgical approach is unclear; however, previous data suggested that coronary artery bypass grafting might improve survival rate compared to that for medical therapy. [18] In recent years, the use of the percutaneous approach has increased as technology has developed and improved. Although balloon angioplasty and stent implantation or attempting thrombus aspiration carries the risk of distal thromboembolization, some reports have demonstrated favorable outcomes obtained by successful thrombus removal or using balloon angioplasty with or without stenting. [19] In addition, intracoronary infusion of glycoprotein IIb/IIIa inhibitors is safe and effective for ACS patients who have a large intracoronary thrombus. [20] Therefore, percutaneous revascularization or surgical approaches should be considered depending on the structure or shape of the coronary artery, pathophysiology, and the patient's clinical condition. 
